Archeoptix Biomedical Inc. has developed a portable imager that provides CT precision in determining the severity of Traumatic Brain Injury (TBI) and other causes of brain bleeds (Stroke in particular – distinguishing hemorrhagic vs. ischemic stroke). Our technologies have the potential to change the way TBI (and Stroke) is managed globally. TBI is the single largest healthcare cost in the modern world, with 69 million affected globally every year. We have a strong and experienced team, and we have a very strong IP portfolio.
Milestones achieved:
1) Health Canada approvals (2) with expected launch in Canada Q2 2024
2) MDSAP certification for Canada (adding US, Japan and Brazil this year).
3) Manufacturing partner in Canada
Work moving forward:
1) Commence/complete clinical trial in Kingston, ON (Q2)
2) Submit to FDA under 510(K) by Q2
3) Other regulatory approvals (EU, Japan, Brazil)
4) Continue outreach to establish a Strategic partner
5) RAISE FUNDING.